Advertisement

Latest News

Taha Qazi, MD: Using Tofacitinib to Improve Treatment Response in Acute Severe Ulcerative Colitis

44 minutes ago

Qazi discusses tofacitinib’s role in acute severe ulcerative colitis management as a potential first-line therapy to increase treatment responsiveness.

Results of VISIBLE Trial in Patients With Skin of Color

56 minutes ago

Dermatology experts highlight VISIBLE trial results when using guselkumab in patients with skin of color.

Guselkumab in Patients With Skin of Color: VISIBLE Trial Design

1 hour ago

Dr Linda Stein Gold, Dr Mona Shahriari and Dr Seemal Desai discuss VISIBLE trial, a randomized clinical trial specifically designed to examine treatment outcomes with guselkumab in patients with skin of color.

Tofacitinib in Acute Severe Ulcerative Colitis (TACOS): A Randomized Controlled Trial

1 hour ago

Findings from a novel study supports the JAK inhibitor tofacitinib as a potential first-line therapy for ASUC.

Taha Qazi, MD: Blue-C Multi-Target Stool DNA Test, Other Noninvasive Options for CRC Screening

2 hours ago

Qazi discusses a review of the BLUE-C trial and explains the rise of noninvasive CRC screening and surveillance options, but highlights the need for colonoscopy nonetheless.

Advertisement
Advertisement